Should metformin still be the first-line of treatment in type 2 diabetes mellitus? A comprehensive review and suggested algorithm

Publication date: Available online 23 April 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Azza Khalifa Bin Hussain, Elamin Abdelgadir, Fauzia Rashid, Abeer Al Haj, Puja Thadani, Alaaeldin M.K. BashierAbstractFor more than a century, the high occurrences of coronary and peripheral artery diseases in diabetes mellitus patients has been well recognised; despite that, the ability to improve CV event rates by optimizing glycaemic control has remained elusive. Nevertheless, the last decade has seen several cardiovascular outcome clinical trials (CVOTs) of many antihyperglycemic agents that reported promising results for cardiovascular and renal outcomes. This leads to a hot debate on the ideal drug choice for first-line treatment in T2DM. The purpose of this paper is to review the evidence supporting the use of metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors and incretin-based therapies for the management of individuals with T2DM and, discuss the rationale for selection.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research

Related Links:

Abdominal obesity and presence of the metabolic syndrome (MetS) significantly increase the risk of developing diseases such as Type 2 diabetes mellitus (T2DM) with escalating emergence of MetS and T2DM constit...
Source: BMC Endocrine Disorders - Category: Endocrinology Authors: Tags: Study protocol Source Type: research
AbstractCardiovascular diseases (CVD) are one of the leading causes of death worldwide. Testosterone (T) is an important sex hormone that triggers several genomic and non-genomic pathways, leading to improvements of several cardiovascular risk factors and quality of life in men. At the vascular level, the key effect of T is the vasorelaxation. This review discusses the molecular pathways and clinical implications of T in the vascular system. Firstly, the mechanisms involved in the T vasodilator effect will be presented. Then, it will be discussed the association of T with the main risks for CVD, namely metabolic syndrome, ...
Source: Journal of Cardiovascular Translational Research - Category: Cardiology Source Type: research
Publication date: Available online 6 December 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Biswapriya B. Misra, Anoop MisraAbstractT2DM, variously known as diabetes mellitus type 2, adult-onset diabetes; noninsulin-dependent diabetes mellitus (NIDDM) is a global silent killer, with> 450 million adults affected worldwide. A diverse array of non-modifiable risk factors such as family history, age (>45 yrs), race/ethnicity, and history of gestational diabetes) and modifiable risk factors such as physical inactivity, high body fat or body weight, high blood pressure and high chol...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
ska M Abstract In the study, 305 patients of both genders were enrolled and divided into three groups: obese (BMI> 30 kg/m2), patients who were diagnosed type 2 diabetes mellitus (T2DM), and control, normal weight healthy volunteers. At least one of ten different phthalate metabolites was determined in the urine samples of 49.84% all enrolled participants. In the obese subgroup, the sum of all urinary phthalate metabolites was positively associated with TG levels (p = 0.031) together with derived TC/HDL and TG/HDL ratios (p = 0.023 and 0.015), respectively. Urinary MEP concentration was positively correlated wi...
Source: Environmental Science and Pollution Research International - Category: Environmental Health Authors: Tags: Environ Sci Pollut Res Int Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Prediabetes has been proposed as a risk factor for the development of type 2 diabetes mellitus (DM2) and cardiovascular disease (CVD). Despite the clinical importance of prediabetes, little is known about the ...
Source: Diabetology and Metabolic Syndrome - Category: Endocrinology Authors: Tags: Research Source Type: research
This study sought to examine the effectiveness of a personalized, community-based exercise program at reducing MetS severity and consequently Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) risk. One-hundred and fifty physically inactive participants (aged 18–83 years) were randomized to a non-exercise control group (n = 75; instructed to continue their usual lifestyle habits) or treatment group (n = 75). Participants randomized to the treatment group completed a 12 week personalized exercise training program based on the American Council on Exercise (ACE) Integrated Fitness Training (IFT) model ...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
This article is protected by copyright. All rights reserved
Source: Molecular Nutrition and Food Research - Category: Food Science Authors: Tags: Review Source Type: research
ConclusionsThe present study indicates salivary nitric oxide level was a predictor of xerostomia in diabetic patients. More longitudinal studies are necessary to understand the association of salivary NO level with diabetes-induced xerostomia.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
CONCLUSIONS: Taken together, these data demonstrate that CRISPLD2 is a circulating adipokine that may regulate adipocyte remodeling during weight loss. PMID: 31746554 [PubMed - in process]
Source: Obesity - Category: Eating Disorders & Weight Management Authors: Tags: Obesity (Silver Spring) Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Incretin Therapy | Metabolic Syndrome | Metformin | SGLT2 Inhibitors | Sodium